Summary of Significant Accounting Policies - Revenue (Details) - USD ($)	12 Months Ended
Jul. 31, 2020	Jul. 31, 2019
Revenue recognised	$ 2,661,396	$ 6,203,761
Product Sales
Revenue recognised	2,643,228	105,432
Management Service
Revenue recognised	18,168	370,118
Pharmacy Sales
Revenue recognised	0	5,409,644
Laboratory Sales
Revenue recognised	$ 0	$ 318,567

The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.

Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Name:	us-gaap_RecognitionOfDeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration